Beijing Tiantan Biological Products Corporation Ltd., a biopharma company, will acquire a 90% interest in Chengdu Rongsheng Pharmaceutical Co., Ltd. for $84 million. Tiantan will use a combination of stock and cash to make the purchase. At the same time, the company said it will spend 1 billion RMB ($150 million) to build a modernized vaccine manufacturing facility in Daxing.  More details...

Stock Symbol: (SHSE: 600161)